about
Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countriesRaltegravir pharmacokinetics during pregnancy.Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study.Mode of delivery and neonatal respiratory morbidity among HIV-exposed newborns in Latin America and the Caribbean: NISDI Perinatal-LILAC Studies.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil.Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Antiretroviral adherence during pregnancy and postpartum in Latin America.Three postpartum antiretroviral regimens to prevent intrapartum HIV infectionPharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancyMissed opportunities for prevention of mother-to-child transmission of HIV-1 in the NISDI Perinatal and LILAC cohorts.Adherence to antiretroviral prophylaxis during early infancy in Latin America.Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.Repeat pregnancy in women with HIV infection in Latin America and the Caribbean.Reduced indinavir exposure during pregnancy.Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes.Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Delivery After 40 Weeks of Gestation in Pregnant Women With Well-Controlled Human Immunodeficiency Virus.Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection.Long-term postpartum adherence to antiretroviral drugs among women in Latin America.[Silence in the daily life of the adolescent with HIV/AIDS].Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities.Response to 'Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients' by Mariné-Barjoan et al.Comments on the brief report "Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I".First-line treatment for tinea capitis.Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission.HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study.Squamous intraepithelial lesions in HIV-infected women: prevalence, incidence, progression and regression.Infectious Morbidity, Mortality and Nutrition in HIV-Exposed, Uninfected, Formula Fed Infants: Results from the HPTN 040/PACTG 1043 Trial.Congenital CMV and HIV Perinatal Transmission.Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection
P50
Q33715492-1F4F0D56-15C5-4876-8DB7-80B2DFC45B8FQ34422111-E3436585-9E93-409E-B6F0-0596E5D5284BQ35156725-B3E2EEB8-BBFA-4336-A669-FEB5BAE459C9Q36011836-6781258D-E885-456D-B13C-A6E2DC9E566CQ36084313-4DC04561-BA9F-47A4-8261-39A86CCF2CEAQ36154839-08468DA7-8DFA-47E3-9548-8593EF2600E8Q36187641-AFE299A2-FC70-4910-B432-28E21429B8B2Q36291883-8F835C87-44AB-4106-B99B-CB9702380AB6Q36662110-095C68C7-BBCB-4CC4-9540-35430B65E732Q36763067-380FF465-2FC0-41D7-913F-7EFCFD2D8BFDQ36931935-79B2F0C2-8CAA-4312-84F3-0F81DC7F9218Q37006119-2B9AE852-5719-4504-8A58-B52F47B75D05Q37013956-9A0D75C9-5999-44A1-B13D-16F19C250711Q37056329-9DF62FC3-B1D4-4640-BC9A-4380085B4571Q37161917-EEFB7220-A5BA-41F4-B26D-056F3884CA04Q37551251-78A7A9A3-A766-4E9D-B55F-D12DC5832302Q37836433-078965DD-D2B3-476D-A360-C7E866351CD3Q38801873-2F64AD74-A858-4954-87AD-75F2B8D932A1Q40087657-C37DAE59-2719-4F39-9F1B-C308FB541D57Q40261944-6375B416-53B3-4470-873F-86DE22492DC2Q40990123-9F1CBE47-B4A3-4CA5-84A8-C53CB32C9BF7Q43408748-4380256B-2B27-46AA-A3DB-6EA4BDFCAFACQ44245024-0A08361C-9716-45BF-AD69-953045CFB370Q45423724-AA68017C-E769-423D-9777-C0F39E367A14Q45478811-EA03BF84-EFCF-476D-8FDD-E611CDC4E614Q46629415-43049362-374F-4DD7-91E8-79190F41D0D6Q48303065-6DF6A305-DC80-4C88-9DA8-CA6D40EA95BBQ49617530-64BBB73F-5B19-468A-A968-037C6AADB3F0Q51875535-0A0067B1-CC84-43CE-B7E0-7B8B6502ECA2Q54214490-03C00671-9B6C-445B-A5DC-4A77263EDEDCQ54257908-BDF03B11-B278-4730-9F18-D4B3FBFDD787Q57953574-144C81FA-2F3B-4DEA-B5A3-26901278D57F
P50
name
Regis Kreitchmann
@ast
Regis Kreitchmann
@en
Regis Kreitchmann
@es
Regis Kreitchmann
@nl
type
label
Regis Kreitchmann
@ast
Regis Kreitchmann
@en
Regis Kreitchmann
@es
Regis Kreitchmann
@nl
prefLabel
Regis Kreitchmann
@ast
Regis Kreitchmann
@en
Regis Kreitchmann
@es
Regis Kreitchmann
@nl